Exchange: NASDAQ·Updated 04:10 PM EST

RDHL News

News
all
press releases
RedHill Biopharma (Nasdaq: RDHL) Highlights Strategic Transformation and Expanded Commercial Growth Strategy in Virtual Investor "What This Means" Segment
RedHill Biopharma (Nasdaq: RDHL) Highlights Strategic Transformation and Expanded Commercial Growth Strategy in Virtual Investor "What This Means" Segment RedHill Biopharma (Nasdaq: RDHL) Highlights Strategic Transformation and Expanded Commercial Growth Strategy in Virtual Investor "What This...
PR Newswire
RedHill Biopharma (Nasdaq: RDHL) Highlights Strategic Transformation and Expanded Commercial Growth Strategy in Virtual Investor "What This Means" Segment
RedHill Biopharma (Nasdaq: RDHL) Highlights Strategic Transformation and Expanded Commercial Growth Strategy in Virtual Investor "What This Means" Segment RedHill Biopharma (Nasdaq: RDHL) Highlights Strategic Transformation and Expanded Commercial Growth Strategy in Virtual Investor "What This...
PR Newswire
More News
Two Leading Labs Confirm RHB-204 MAP-Killing Effect for RedHill's Crohn's Disease Candidate Two Leading Labs Confirm RHB-204 MAP-Killing Effect for RedHill's Crohn's Disease CandidatePR NewswireRALEIGH, N.C. and TEL AVIV, Israel, Nov. 2, 2026 In vitro studies, undertaken by two leading microbiology...
PR Newswire
$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma $2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple MyelomaPR NewswireTEL...
PR Newswire
Weekly Losses Deepen As Small Caps Lag And Yields Edge Higher Into Earnings Gauntlet Weekly Losses Deepen As Small Caps Lag And Yields Edge Higher Into Earnings GauntletPR NewswireNEW YORK, Oct. 1, 2026Stock Preachers News CommentaryNEW YORK, Oct. 1, 2026 /PRNewswire/ --Stocks closed out a choppy...
PR Newswire
RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial ResultsPR NewswireTEL AVIV, Israel and RALEIGH, N.C., Sept. 30, 2026Executing a full strategic portfolio reset, RedHill is now a...
PR Newswire
Gainers Redhill Biopharma (NASDAQ:RDHL) stock increased by 69.4% to $1.12 during Monday's regular session. The company's market cap stands at $4.0 million. CollPlant Biotechnologies (NASDAQ:CLGN) sharesread more...
Benzinga
An upfront cash infusion from a commercial asset sale sparked a massive morning rally in specialty pharma today, highlighting how non-dilutive liquidity events can rapidly re-rate microcap balance sheets. When a developer monetizes its majority stake in an approved drug to a global manufacturing partner, the market quickly rewards the immediate cash injection. RedHill Biopharma Ltd. (Nasdaq: RDHL) advanced Monday after divesting its Talicia business to a subsidiary of Apotex Health Corp. (TSX: APTX) for $18M in cash upfront, plus up to additional $35M tied to worldwide net-sales ...
AllPennyStocks.com
An upfront cash infusion from a commercial asset sale sparked a massive morning rally in specialty pharma today, highlighting how non-dilutive liquidity events can rapidly re-rate microcap balance sheets. When a developer monetizes its majority stake in an approved drug to a global manufacturing partner, the market quickly rewards the immediate cash injection. RedHill Biopharma Ltd. (Nasdaq: RDHL) advanced Monday after divesting its Talicia business to a subsidiary of Apotex Health Corp. (TSX: APTX) for $18M in cash upfront, plus up to additional $35M tied to worldwide net-sales ...
AllPennyStocks.com
RedHill Biopharma divests Talicia to Apotex, boosting liquidity and funding its commercial growth strategy and RHB-102 development.read more...
Benzinga
RedHill Biopharma (NASDAQ:RDHL) just sold the product that defined its U.S. commercial identity. RedHill announced it divested its remaining 70% stake in Talicia to a subsidiary of newly public Apotex Health (TSX:APTX) for $18 million in cash upfront plus up to $35 million in worldwide net sales milestones. Apotex already owned the other 30% after buying Cumberland’s (NASDAQ:CPIX) U.S. branded business earlier this year. The sale consolidates Talicia under one owner and gives RedHill the liquidity it says it needs to rebuild a larger gastrointestinal franchise.
24-7 Market News

Advertisement|Remove ads.